Lucy Coassin
Chief Executive Officer, Interim
Lucy Coassin is CEO of Hawthorne Health and a Director at Northpond Ventures. She serves as a board director at Inflammatix, Octave Bioscience, SimBioSys, and Vital Biosciences, and a board observer at Faro Health, Triumvira, Vizgen, and Slingshot Biosciences. Previously, Lucy served on the boards of Story Health (acquired by Innovaccer) and Hawthorne Health.
Prior to Northpond, she was Head of Pharma at Current Health (a Northpond portfolio company, acquired by Best Buy). She has 15 years of experience commercializing technology from product launch to widespread adoption. Lucy has held business development and commercial roles at digital health and life science tool companies including Science 37 (NASDAQ: SNCE), Farcast Biosciences, Genentech, and Life Technologies (acquired by Thermo Fisher, NYSE: TMO). Lucy received her MBA from the Stanford Graduate School of Business and a B.S. with distinction in Chemistry from Duke University.












